Ozenoxacin

Ozenoxacin
Clinical data
Trade names	Ozanex; Xepi
ATC code	D06AX14 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 1-Cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
CAS Number	245765-41-7;
PubChem CID	9863827;
ChemSpider	8039521;
KEGG	D09544;
Chemical and physical data
Formula	C21H21N3O3
Molar mass	363.42 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\3c1c(c(c(cc1)c2cc(c(nc2)NC)C)C)N(/C=C/3C(=O)O)C4CC4;
	InChI InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27); Key:XPIJWUTXQAGSLK-UHFFFAOYSA-N;

Ozenoxacin (INN; trade names Ozaenex and Xepi) is a quinolone antibiotic being approved for the treatment of impetigo.^[1] A 1% topical cream is approved for treatment of impetigo in Canada^[2] and in the United States.^[3]

Ozenoxacin is active against some bacteria that have developed resistance to currently used quinolone and fluoroquinolone antibiotics.^[4]

References

↑ "Ferrer successfully completes a phase III clinical trial in adult and paediatric patients with impetigo for novel antibacterial compound Ozenoxacin". drugs.com. June 2013.
↑ "Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)" (Press release). Cipher Pharmaceuticals Inc.
↑ "Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi™ (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo" (Press release). Medimetriks Pharmaceuticals, Inc.
↑ López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J (Dec 2013). "In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria". Antimicrob Agents Chemother. 57 (12): 6389–6392. doi:10.1128/AAC.01509-13. PMC 3837899. PMID 24080666.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Ferrer successfully completes a phase III clinical trial in adult and paediatric patients with impetigo for novel antibacterial compound Ozenoxacin". drugs.com. June 2013.

[2] "Cipher Pharmaceuticals Receives Health Canada Approval of OZANEX (ozenoxacin cream 1%)" (Press release). Cipher Pharmaceuticals Inc.

[3] "Medimetriks Pharmaceuticals, Inc. Receives FDA Approval for Xepi™ (ozenoxacin) Cream, 1%, a Novel Topical Antibiotic for Impetigo" (Press release). Medimetriks Pharmaceuticals, Inc.

[4] López Y, Tato M, Espinal P, Garcia-Alonso F, Gargallo-Viola D, Cantón R, Vila J (Dec 2013). "In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria". Antimicrob Agents Chemother. 57 (12): 6389–6392. doi:10.1128/AAC.01509-13. PMC 3837899. PMID 24080666.